Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 46, 2008, Pages 17908-17912

  Senti, Gabriela ^a,b   Prinz Vavricka, Bettina M ^a   Erdmann, Iris ^a   Diaz, Mella I ^c   Markus, Richard ^c   McCormack, Stephen J ^c   Simard, John J ^a,c   Wüthrich, Brunello ^a   Crameri, Reto ^d   Graf, Nicole ^a   Johansen, Pål ^a   Kündig, Thomas M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c MannKind Corporation   (United States)

^d SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

Author keywords

Allergy; Pollen; Rhinoconjunctivitis

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; DESLORATADINE; EMEDASTINE; IMMUNOGLOBULIN E; MOMETASONE FUROATE; POLLEN EXTRACT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HAY FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INJECTION SITE PAIN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NOSE PROVOCATION TEST; PRICK TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; UNSPECIFIED SIDE EFFECT; VEIN PUNCTURE;

ADOLESCENT; ADULT; AGED; ALLERGENS; ANTI-ALLERGIC AGENTS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE; IMMUNOGLOBULIN E; INJECTIONS, INTRALYMPHATIC; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PAIN; SKIN TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 56649120612     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0803725105     Document Type: Article

References (24)

1. Arbes SJ, Jr, Gergen PJ, Elliott L, Zeldin DC (2005) Prevalences of positive skin test responses to 10 common allergens in the US population: Results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 116:377-383.
2. Bousquet J, Lockey R, Malling HJ (1998) Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 102:558-562.
3. Lockey RF (2001) "ARIA": Global guidelines and new forms of allergen immunotherapy. J Allergy Clin Immunol 108:497-499.
4. Varney VA, et al. (1991) Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 302:265-269.
5. Durham SR, et al. (1999) Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341:468-475.
6. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S (2001) Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 31:1392-1397.
7. Moller C, et al. (2002) Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 109:251-256.
8. Anonymous (2005) Epidemiology Surveys and Danske Equities (ALK-Abelló, Hørsholm, Denmark).
9. Stewart GE, 2nd, Lockey RF (1992) Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 90:567-578.
10. Johansen P, et al. (2005) Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol 35:568-574.
11. Maloy KJ, et al. (2001) Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA 98:3299-3303.
12. von Beust BR, et al. (2005) Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. Eur J Immunol 35:1869-1876.
13. Finerty S, et al. (2001) Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus. Vaccine 20:49-58.
14. Lehner T, et al. (1998) Protective mucosal immunity elicited by targeted lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Dev Biol Stand 92:225-235.
15. Mueller UR (1990) Insect Sting Allergy (Gustav Fischer, Stuttgart).
16. Kundig TM, et al. (1995) Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268:1343-1347.
17. Koopman G, et al. (2007) Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques. J Med Virol 79:474-482.
18. Trepel M, Arap W, Pasqualini R (2001) Modulation of the immune response by systemic targeting of antigens to lymph nodes. Cancer Res 61:8110-8112.
19. Lehner T, et al. (1999) The effect of route of immunization on mucosal immunity and protection. J Infect Dis 179(Suppl 3):S489-S492.
20. Popper P, Mantyh CR, Vigna SR, Maggio JE, Mantyh PW (1988) The localization of sensory nerve fibers and receptor binding sites for sensory neuropeptides in canine mesenteric lymph nodes. Peptides 9:257-267.
21. Lockey RF, et al. (1990) The Hymenoptera venom study. III. Safety of venom immunotherapy. J Allergy Clin Immunol 86:775-780.
22. Riechelmann H, et al. (2003) Application of the nasal provocation test on diseases of the upper airways. Position paper of the German Society for Allergology and Clinical Immunology (ENT Section) in cooperation with the Working Team for Clinical Immunology. Laryngorhinootologie 82:183-188 (in German).
23. (1993) Position paper: Allergen standardization and skin tests. The European Academy of Allergology and Clinical Immunology. Allergy 48:48-82.
24. Sussman GL, Harvey RP, Schocket AL (1982) Evaluation of skin test response using two techniques of measurement. Ann Allergy 48:75-77.